Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below 200-Day Moving Average of $58.09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $58.09 and traded as low as $51.02. Enanta Pharmaceuticals shares last traded at $52.65, with a volume of 164,027 shares trading hands.

Analyst Ratings Changes

A number of brokerages recently commented on ENTA. JMP Securities increased their price target on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a “market outperform” rating in a report on Tuesday, August 9th. Oppenheimer increased their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a “market perform” rating in a report on Wednesday, August 10th. Royal Bank of Canada reduced their price target on Enanta Pharmaceuticals from $67.00 to $66.00 and set a “sector perform” rating for the company in a report on Tuesday, August 9th. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th. Finally, SVB Leerink increased their target price on Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a “market perform” rating in a report on Monday, August 1st. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.63.

Enanta Pharmaceuticals Stock Performance

The firm has a market cap of $1.09 billion, a P/E ratio of -8.98 and a beta of 0.55. The firm has a fifty day moving average of $60.55 and a 200-day moving average of $58.09.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last posted its earnings results on Monday, August 8th. The biotechnology company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.17). Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative return on equity of 32.42%. The business had revenue of $19.48 million during the quarter, compared to analyst estimates of $20.73 million. During the same quarter in the prior year, the business earned ($1.19) earnings per share. The firm’s revenue was down 9.9% compared to the same quarter last year. Equities research analysts expect that Enanta Pharmaceuticals, Inc. will post -5.75 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Signaturefd LLC increased its position in shares of Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 182 shares during the period. Captrust Financial Advisors boosted its stake in shares of Enanta Pharmaceuticals by 343.8% during the 1st quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 660 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 164.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 750 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $114,000. Finally, KBC Group NV bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth $113,000. 97.09% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Recommended Stories

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.